Analysis of Transplant-Eligible Patients (Pts) Who Received Frontline Daratumumab (DARA)-Based Quadruplet Therapy for the Treatment of Newly Diagnosed Multiple Myeloma (NDMM) with High-Risk Cytogenetic Abnormalities (HRCA) in the Griffin and Master Studies

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood 2022-11, Vol.140 (Supplement 1), p.10144-10147
Hauptverfasser:	Callander, Natalie, Silbermann, Rebecca, Kaufman, Jonathan L., Godby, Kelly N., Laubach, Jacob P, Schmidt, Timothy Martin, Sborov, Douglas W, Medvedova, Eva, Reeves, Brandi, Dhakal, Binod, Rodriguez, Cesar, Chhabra, Saurabh, Chari, Ajai, Bal, Susan, Anderson, Larry D., Dholaria, Bhagirathbhai, Nathwani, Nitya, Hari, Parameswaran, Shah, Nina, Bumma, Naresh, Holstein, Sarah A., Costello, Caitlin, Jakubowiak, Andrzej, Wildes, Tanya M., Orlowski, Robert Z., Shain, Ken H., Cowan, Andrew J., Pei, Huiling, Cortoos, Annelore, Patel, Sharmila, Lin, Thomas S., Giri, Smith, Costa, Luciano J., Richardson, Paul G., Usmani, Saad, Voorhees, Peter M.
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!